Tissue Repair Ltd (TRP.AX)
Tissue Repair Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in Chatswood, NSW, AU. The stock last traded at $0.09, up 0.00% on the session, giving a market capitalisation of $5.2M. Its beta of 0.22 implies it has historically moved less than the broad market.
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recovery following cosmetic procedures. Its product pipeline features TR-987 and a suite of innovative dressings and matrices, including the proprietary Glucoprime technology. These are specifically engineered to address challenging conditions such as chronic wounds, burns, and other complex dermal injuries. Additionally, TR Pro+ is being developed for post-procedure care after minimally invasive aesthetic treatments. Beyond these core programs, Tissue Repair is also exploring applications in animal health, novel bandage and scaffold technologies, and various other therapeutic areas. The company was founded in 2012 and operates from its headquarters in Sydney, Australia.
Tissue Repair Ltd is most often compared with the following Healthcare names: